ASSESSMENT OF INSULIN PRODUCTED PANCREATIC FUNCTION IN PATIENTS WITH DIABETES MELLITUS WITH DIFFERENT DEGREES OF INSULIN DEFICIENCY
DOI:
https://doi.org/10.21856/j-PEP.2016.4.06Keywords:
type 1 and 2 diabetes mellitus, slowly progressive autoimmune diabetes of adults, C-peptide, an absolute insulin deficiencyAbstract
The study involved 162 people, including 61 patients with type 1 diabetes mellitus (DM), 70 patients with slowly progressive autoimmune diabetes of adults and 31 patients with type 2 diabetes with the development of insulin dependence after more than 10 years since the disease onset. Based on a comparative analysis of fasting C-peptide levels in patients of observation groups the different degree of insulin secretion reduction was set. Thus in patients with type 1 diabetes mellitus severity of absolute insulin deficiency is not a determining factor of the variant of the disease (relatively stable or labile). In general, the definition of C-peptide in patients with diabetes is a reliable criterion by which we can judge the functional activity of β-cells, even in the appointment of insulin. In doubtful cases it is advisable to carry out the research of C-peptide in the dynamics of observation.
References
Holman RR, Paul SK, Bethel MA, et al. N Engl J Med 2008; 359(15):1577-1589. doi: http://dx.doi.org/10.1056/NEJMoa0806470.
Nathan DM, DCCT/EDIC Research Group. Diabetes Care 2014; 37(1):9-16. doi: http://dx.doi.org/10.2337/dc13-1647
American Diabetes Association. Standards of Medical Care in Diabetes—2016: Summary of Revisions. Diabetes Care 2016; 39(1):S4-S5.
International Diabetes Federation. Annual Report 2015: 28 p, available at: www.idf.org/sites/default/files/IDFAnnualReport_2015_WEB.pdf.
Ozougwu JC, Obimba KC, Belonwu CD, et al. J Physiol Pathophysiol 2013; 4(4):46-57. doi: http://dx.doi.org/10.1056/NEJMoa0806470
Dib SA. Arq Bras Endocrinol Metab 2008; 52(2):205-218. doi: http://dx.doi.org/10.1590/S0004-27302008000200001
Jones AG, Hattersley AT. Diabet Med 2013; 30(7): 803-817. doi: http://dx.doi.org/10.1111/dme.12159
Donath MY, Ehses JA, Maedler K, et al. Diabetes 2005; 54(2):S108-S113. doi: http://dx.doi.org/10.2337/diabetes.54.suppl_2.S108
Velykyh NJe. Osoblyvosti rozvytku absoljutnoi’ insulinovoi’ nedostatnosti u hvoryh na cukrovyj diabet 2 typu ta obg’runtuvannja dyferencijovanoi’ terapii’, Harkiv, 2008: 20 p.
Smolen HJ, Murphy DR, Gahn JC, et al. J Manag Care Spec Pharm 2014; 20(9):968-984.
Tuomi T, Santoro N, Caprio S, et al. Lancet 2014; 383(9922):1084-1094. doi: http://dx.doi.org/10.1016/S0140-67361362219-9
Corcillo A, Jornayvaz FR. Rev Med Suisse 2015; 11(477):1234-1237.
Naik RG, Brooks-Worrell BM, Palmer JP. J Clin Endocrinol Metab 2009; 94(12):4635–4644. doi: http://dx.doi.org/10.1210/jc.2009-1120
Seok H, Lee BW. Diabetes Metab J 2012; 36(2):116-119. doi: http://dx.doi.org/10.4093/dmj.2012.36.2.116
Palmer JP, Fleming GA, Greenbaum CJ, et al. Diabetes 2004; 53(1):250-264. doi: http://dx.doi.org/10.2337/diabetes.53.1.250
Junkerov VI, Grigor’ev FG. Matematiko-statisticheskaja obrabotka dannyh medicinskih issledovanij, Sankt-Peterburg, 2002: 266 p.
Tyhonova TM. Povil’no progresujuchyj avtoimunnyj diabet doroslyh: etapy rozvytku, kliniko-imunologichni ta genetychni markery, obg’runtuvannja patogenetychnoi’ terapii’, Harkiv, 2015: 47 p.
Maedler K, Carr RD, Bosco D, et al. J Clin Endocrinol Metab 2005; 90(1):501-506. doi: http://dx.doi.org/10.1210/jc.2004-0699
Tomita T. Bosnian J Basic Med Sci 2016; 16(3):162-179.
Meneghini LF. Diabetes Care 2009; 32(2):S266-S269. doi: http://dx.doi.org/10.2337/dc09-S320